凱萊英(06821.HK)第三季度收入14.43億元 剔除大訂單同比增長12.23%
格隆匯10月29日丨凱萊英(06821.HK)公吿，2024年第三季度，公司實現收入人民幣14.43億元，剔除大訂單同比增長12.23%，環比上季度增長11.21%；其中小分子業務實現收入人民幣11.92億元，剔除大訂單同比增長18.89%，環比增長22.52%，新興業務實現收入人民幣2.45億元，同比下降13.26%，從在手訂單和執行情況看，第四季度新興業務將重新恢復增長態勢。
2024年前三季度，公司實現營業總收入人民幣41.40億元，同比下降35.14%，剔除大訂單影響後同比增長4.48%，小分子業務收入人民幣33.87億元，剔除大訂單影響後同比增長7.71%，新興業務收入人民幣7.45億元，同比下降8.37%，主要受生物醫藥融資復甦緩慢影響所致；來自大製藥公司收入人民幣20.13億元，剔除大訂單影響後同比增長11.10%；來自中小製藥公司收入人民幣21.27億元，同比下降1.09%，其中來自境外中小製藥公司收入人民幣10.78億元，同比下降0.03%。
2024年前三季度，公司實現業務毛利率43.60%，剔除大訂單影響後同比下降1.02個百分點，其中小分子業務毛利率48.89%，剔除大訂單影響後同比提升1.19個百分點，隨着公司各項成本管控措施的有效實施，以及臨牀後期項目和商業化項目增多，小分子業務已基本消化因大訂單增加的各項資源；新興業務毛利率19.97%，同比下降12.99個百分點，主要受國內市場持續低迷、部分業務仍處於產能爬坡期等因素影響，隨着項目交付持續增加，特別是海外項目的增多，這一問題會逐漸得到緩解。
儘管2024年行業仍面臨諸多挑戰，但國際製藥行業專業化分工趨勢未發生改變，醫藥外包服務滲透率仍在提升，小分子藥物外包需求保持穩定，同時多肽、ADC、小核酸等藥物類別市場持續活躍，都帶來了新的機遇和增量市場空間。報吿期內，公司持續升級優化管理運營體系，全面加速全球化佈局，歐洲首個研發及中試基地Sand wich Site已投入運營，並已開始承接新訂單，進一步支撐公司全球供應鏈體系的完善，並以此為依託，推進海外商業化產能佈局；加速多肽業務拓展和產能建設，獲得多個跨國製藥公司的多肽臨牀中後期項目，與國內重要客户簽訂GLP-1多肽商業化訂單，截至報吿期末多肽固相合成產能超20,000L，以滿足國內外客户固相多肽商業化生產需求；公司持續強化頭部客户帶動力，積極拓展海內外市場，擴大服務客户羣體，新簽訂單持續保持良好態勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
